Acza Kalica Buarque da Silva
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Acza Kalica Buarque da Silva has a total of 75 co-authors. Here are the top co-authors by number of shared publications:
- Ana Carolina Cardoso Cordeiro2 shared publications
- Ana Gabriela Santos Fonseca Selvio2 shared publications
- Antonio Mutarelli
Universidade Federal de Minas Gerais, Brazil; Massachusetts General Hospital, USA
2 shared publications - Bianca Gabriele Martins Ribeiro2 shared publications
Brenno Laerth Neves Santana
2 shared publications- Bruna Araújo de Aguiar Franco2 shared publications
Latest Publications
- Open Access
- 1 January 2026
- Published by Wiley in Anesthesiology Research and Practice
- Vol. 2026 (1) , 5856805
Effect of Perioperative Benzodiazepine Use on Postoperative Delirium in Patients Undergoing Cardiac Surgery: A Systematic Review and Meta‐Analysis
Introduction: Cardiac surgery anesthesia is associated with risks such as postoperative delirium (POD) and stress‐related responses. Benzodiazepines have been used perioperatively to reduce anxiety and promote hemodynamic control. However, their use may increase the risk of delirium, particularly in older adults. This systematic review and meta‐analysis aims to evaluate the impact of perioperative benzodiazepine use on the incidence of POD in patients undergoing cardiac surgery. Methods: We systematically searched for randomized controlled trials (RCTs) and observational studies comparing benzodiazepines with placebo or nonbenzodiazepine drugs in adults undergoing cardiac surgery. The primary outcome was POD incidence; secondary outcomes included mini‐mental state examination (MMSE), ICU length of stay, and time to extubation. For dichotomous outcomes, odds ratios (ORs) with 95% confidence intervals (CIs) were calculated, while mean differences (MDs) were used for continuous outcomes. Analyses were performed using R 4.4.3. Results: Eight studies were included, comprising 36,301 patients, of whom 20,747 (68.5%) received benzodiazepines. Follow‐up ranged from 1 day to 12 months. There were no significant differences between groups in the incidence of POD (OR 1.05; 95% CI: 0.88 to 1.25; p = 0.55; I 2 = 83%). Similarly, there were no significant difference in MMSE score (MD ‐0.11; 95% CI: −3.17 to 2.95; p = 0.94; I 2 = 70%), ICU length of stay (MD 4.72 h; 95% CI: −1.37 to 10.80; p = 0.13; I 2 = 99%), and time to extubation (MD ‐0.53 h; 95% CI: −2.16 to 1.09; p = 0.52; I 2 = 72%). Conclusion: Perioperative benzodiazepine use was not significantly associated with POD or with secondary outcomes in adults undergoing cardiac surgery.
- 1 January 2026
- Published by Wiley in Anesthesiology Research and Practice
- Vol. 2026 (1) , 5856805
Open AccessEffect of Perioperative Benzodiazepine Use on Postoperative Delirium in Patients Undergoing Cardiac Surgery: A Systematic Review and Meta‐Analysis
Introduction: Cardiac surgery anesthesia is associated with risks such as postoperative delirium (POD) and stress‐related responses. Benzodiazepines have been used perioperatively to reduce anxiety and promote hemodynamic control. However, their use may increase the risk of delirium, particularly in older adults. This systematic review and meta‐analysis aims to evaluate the impact of perioperative benzodiazepine use on the incidence of POD in patients undergoing cardiac surgery. Methods: We systematically searched for randomized controlled trials (RCTs) and observational studies comparing benzodiazepines with placebo or nonbenzodiazepine drugs in adults undergoing cardiac surgery. The primary outcome was POD incidence; secondary outcomes included mini‐mental state examination (MMSE), ICU length of stay, and time to extubation. For dichotomous outcomes, odds ratios (ORs) with 95% confidence intervals (CIs) were calculated, while mean differences (MDs) were used for continuous outcomes. Analyses were performed using R 4.4.3. Results: Eight studies were included, comprising 36,301 patients, of whom 20,747 (68.5%) received benzodiazepines. Follow‐up ranged from 1 day to 12 months. There were no significant differences between groups in the incidence of POD (OR 1.05; 95% CI: 0.88 to 1.25; p = 0.55; I 2 = 83%). Similarly, there were no significant difference in MMSE score (MD ‐0.11; 95% CI: −3.17 to 2.95; p = 0.94; I 2 = 70%), ICU length of stay (MD 4.72 h; 95% CI: −1.37 to 10.80; p = 0.13; I 2 = 99%), and time to extubation (MD ‐0.53 h; 95% CI: −2.16 to 1.09; p = 0.52; I 2 = 72%). Conclusion: Perioperative benzodiazepine use was not significantly associated with POD or with secondary outcomes in adults undergoing cardiac surgery.
- Open Access
- 1 December 2025
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Nephrology
- Vol. 47 (4)
Eficácia da D-manose como profilaxia da infecção recorrente do trato urinário: uma revisão sistemática e metanálise de ensaios clínicos randomizados controlados
Resumo Introdução: As infecções do trato urinário (ITUs) recorrentes afetam significativamente a qualidade de vida devido aos sintomas, aos efeitos sobre a atividade sexual, à dor persistente e ao uso recorrente de antibióticos. Esta revisão sistemática e metanálise teve como objetivo avaliar a eficácia da D-manose na prevenção de ITUs recorrentes. Métodos: Em maio de 2024, realizamos uma busca sistemática nas bases de dados PubMed, EMBASE e Cochrane Library por ensaios clínicos randomizados (ECRs) que comparassem o tratamento com D-manose à ausência de intervenção ou à terapia antibiótica padrão em pacientes com alto risco de ITU recorrente. Aplicamos um modelo de efeitos aleatórios para agrupar os riscos relativos (RR) e os intervalos de confiança (IC) de 95%. Resultados: Incluímos 6 ECRs envolvendo 1.167 participantes, dos quais 534 receberam D-manose e 521 (97,6%) eram mulheres. A D-manose não se associou a uma redução na ITU recorrente em comparação ao grupo controle (RR: 0,57; IC 95% 0,29 – 1,15; p < 0,01) ou ao uso de antibióticos (RR: 0,39; IC 95% 0,12 – 1,25; p < 0,01). Análises adicionais demonstraram que a D-manose não melhorou os desfechos em um subgrupo de mulheres na pós-menopausa. Conclusão: Nesta metanálise de ECRs, a D-manose não reduziu a incidência de ITUs recorrentes em comparação ao grupo controle ou ao tratamento com antibióticos em pacientes de alto risco.
- 1 December 2025
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Nephrology
- Vol. 47 (4)
Open AccessEficácia da D-manose como profilaxia da infecção recorrente do trato urinário: uma revisão sistemática e metanálise de ensaios clínicos randomizados controlados
Resumo Introdução: As infecções do trato urinário (ITUs) recorrentes afetam significativamente a qualidade de vida devido aos sintomas, aos efeitos sobre a atividade sexual, à dor persistente e ao uso recorrente de antibióticos. Esta revisão sistemática e metanálise teve como objetivo avaliar a eficácia da D-manose na prevenção de ITUs recorrentes. Métodos: Em maio de 2024, realizamos uma busca sistemática nas bases de dados PubMed, EMBASE e Cochrane Library por ensaios clínicos randomizados (ECRs) que comparassem o tratamento com D-manose à ausência de intervenção ou à terapia antibiótica padrão em pacientes com alto risco de ITU recorrente. Aplicamos um modelo de efeitos aleatórios para agrupar os riscos relativos (RR) e os intervalos de confiança (IC) de 95%. Resultados: Incluímos 6 ECRs envolvendo 1.167 participantes, dos quais 534 receberam D-manose e 521 (97,6%) eram mulheres. A D-manose não se associou a uma redução na ITU recorrente em comparação ao grupo controle (RR: 0,57; IC 95% 0,29 – 1,15; p < 0,01) ou ao uso de antibióticos (RR: 0,39; IC 95% 0,12 – 1,25; p < 0,01). Análises adicionais demonstraram que a D-manose não melhorou os desfechos em um subgrupo de mulheres na pós-menopausa. Conclusão: Nesta metanálise de ECRs, a D-manose não reduziu a incidência de ITUs recorrentes em comparação ao grupo controle ou ao tratamento com antibióticos em pacientes de alto risco.
- Open Access
- 1 December 2025
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Nephrology
- Vol. 47 (4) , e20250169
Efficacy of D-mannose as prophylaxis of recurrent urinary tract infection: a systematic review and meta-analysis of randomized controlled trials
Introduction: Recurrent urinary tract infections (UTIs) significantly impact the quality of life due to symptoms, effects on sexual activity, persistent pain, and recurrent antibiotic use. This systematic review and meta-analysis aimed to evaluate the efficacy of D-mannose in preventing recurrent UTIs.
- 1 December 2025
- Published by FapUNIFESP (SciELO) in Brazilian Journal of Nephrology
- Vol. 47 (4) , e20250169
Open AccessEfficacy of D-mannose as prophylaxis of recurrent urinary tract infection: a systematic review and meta-analysis of randomized controlled trials
Introduction: Recurrent urinary tract infections (UTIs) significantly impact the quality of life due to symptoms, effects on sexual activity, persistent pain, and recurrent antibiotic use. This systematic review and meta-analysis aimed to evaluate the efficacy of D-mannose in preventing recurrent UTIs.
- Open Access
- 5 March 2025
- Published by RGSA- Revista de Gestao Social e Ambiental in Revista de Gestão Social e Ambiental
- Vol. 19 (3) , e011265
Comparative Study Between Central Venoarterial ECMO and Peripheral Venoarterial ECMO in Patients With Post-Cardiotomy Cardiogenic Shock
Objective: This study aims to compare central and peripheral venoarterial extracorporeal membrane oxygenation (VA-ECMO) approaches in patients with postcardiotomy cardiogenic shock, evaluating outcomes such as in-hospital mortality, vascular complications, and weaning success rates. Theoretical Framework: Postcardiotomy cardiogenic shock is a critical condition associated with high mortality rates, requiring advanced temporary circulatory support. Central VA-ECMO, characterized by direct cannulation of the aorta and right atrium, provides greater hemodynamic stability and physiological support but is associated with higher risks of hemorrhagic and infectious complications. Peripheral ECMO, implanted through femoral access, allows for faster and less complex deployment but is linked to vascular complications, such as limb ischemia and differential hypoxemia. The choice between techniques depends on clinical factors such as hemodynamic status, comorbidities, and the need for emergent or prolonged support. Method: A systematic review was conducted with a temporal scope from 2014 to 2024, including 14 studies identified in the PubMed, Scopus, and Web of Science databases. Inclusion criteria covered studies comparing central and peripheral VA-ECMO in adult patients with postcardiotomy cardiogenic shock, analyzing outcomes such as in-hospital mortality, vascular complications, and weaning success rates. Results and Discussion: Findings indicate that central ECMO is associated with greater hemodynamic stability and higher weaning success rates but presents higher risks of hemorrhagic complications and reoperations. In contrast, peripheral ECMO, more commonly used in emergencies, demonstrated faster deployment and lower bleeding rates but a higher incidence of vascular complications such as limb ischemia. Hybrid strategies and the use of additional devices, such as intra-aortic balloon pumps and Impella, showed potential to optimize outcomes but are associated with high costs and increased complication rates. Research Implications: This study highlights the need for multicenter and long-term clinical trials to refine selection criteria between central and peripheral ECMO, as well as to explore hybrid strategies to improve outcomes. Future research should also evaluate the impact of these techniques on quality of life and cost-effectiveness. Originality/Value: This systematic review provides a comprehensive analysis of the differences between central and peripheral ECMO in patients with postcardiotomy cardiogenic shock, contributing to informed clinical decision-making and the improvement of management protocols.
- 5 March 2025
- Published by RGSA- Revista de Gestao Social e Ambiental in Revista de Gestão Social e Ambiental
- Vol. 19 (3) , e011265
Open AccessComparative Study Between Central Venoarterial ECMO and Peripheral Venoarterial ECMO in Patients With Post-Cardiotomy Cardiogenic Shock
Objective: This study aims to compare central and peripheral venoarterial extracorporeal membrane oxygenation (VA-ECMO) approaches in patients with postcardiotomy cardiogenic shock, evaluating outcomes such as in-hospital mortality, vascular complications, and weaning success rates. Theoretical Framework: Postcardiotomy cardiogenic shock is a critical condition associated with high mortality rates, requiring advanced temporary circulatory support. Central VA-ECMO, characterized by direct cannulation of the aorta and right atrium, provides greater hemodynamic stability and physiological support but is associated with higher risks of hemorrhagic and infectious complications. Peripheral ECMO, implanted through femoral access, allows for faster and less complex deployment but is linked to vascular complications, such as limb ischemia and differential hypoxemia. The choice between techniques depends on clinical factors such as hemodynamic status, comorbidities, and the need for emergent or prolonged support. Method: A systematic review was conducted with a temporal scope from 2014 to 2024, including 14 studies identified in the PubMed, Scopus, and Web of Science databases. Inclusion criteria covered studies comparing central and peripheral VA-ECMO in adult patients with postcardiotomy cardiogenic shock, analyzing outcomes such as in-hospital mortality, vascular complications, and weaning success rates. Results and Discussion: Findings indicate that central ECMO is associated with greater hemodynamic stability and higher weaning success rates but presents higher risks of hemorrhagic complications and reoperations. In contrast, peripheral ECMO, more commonly used in emergencies, demonstrated faster deployment and lower bleeding rates but a higher incidence of vascular complications such as limb ischemia. Hybrid strategies and the use of additional devices, such as intra-aortic balloon pumps and Impella, showed potential to optimize outcomes but are associated with high costs and increased complication rates. Research Implications: This study highlights the need for multicenter and long-term clinical trials to refine selection criteria between central and peripheral ECMO, as well as to explore hybrid strategies to improve outcomes. Future research should also evaluate the impact of these techniques on quality of life and cost-effectiveness. Originality/Value: This systematic review provides a comprehensive analysis of the differences between central and peripheral ECMO in patients with postcardiotomy cardiogenic shock, contributing to informed clinical decision-making and the improvement of management protocols.
- Open Access
- 1 March 2025
- Published by Seven Events in ARACÊ
- Vol. 7 (3) , 13983-14002
ANÁLISE TÉCNICA DA EFICÁCIA TERAPÊUTICA DA INTRADERMOTERAPIA NO TRATAMENTO DA GORDURA LOCALIZADA
A necessidade de um padrão de beleza humano tornou-se um fenômeno comum na sociedade, fazendo com que houvesse a busca por um corpo ideal e sua reavaliação. A gordura local é definida como um distúrbio celular do metabolismo das células de gordura ou seu crescimento anormal, comum nas principais partes do corpo, como: coxas, abdômen e coxas. A Intradermoterapia é um procedimento que usa injeções intradérmicas de agentes lipolíticos altamente diluídos em uma área de gordura localizada. Ademais, este trabalho possui o objetivo de a eficácia da terapia intradérmica (Intradermoterapia) no tratamento gordura localizada. Para isso, a metodologia aplicada é qualitativa e bibliográfica, sendo que revisão literária ocorreu por meio de base de dados do google acadêmico, PubMed, Scielo e demais informações eletrônicas de respaldo no território nacional.
- 1 March 2025
- Published by Seven Events in ARACÊ
- Vol. 7 (3) , 13983-14002
Open AccessANÁLISE TÉCNICA DA EFICÁCIA TERAPÊUTICA DA INTRADERMOTERAPIA NO TRATAMENTO DA GORDURA LOCALIZADA
A necessidade de um padrão de beleza humano tornou-se um fenômeno comum na sociedade, fazendo com que houvesse a busca por um corpo ideal e sua reavaliação. A gordura local é definida como um distúrbio celular do metabolismo das células de gordura ou seu crescimento anormal, comum nas principais partes do corpo, como: coxas, abdômen e coxas. A Intradermoterapia é um procedimento que usa injeções intradérmicas de agentes lipolíticos altamente diluídos em uma área de gordura localizada. Ademais, este trabalho possui o objetivo de a eficácia da terapia intradérmica (Intradermoterapia) no tratamento gordura localizada. Para isso, a metodologia aplicada é qualitativa e bibliográfica, sendo que revisão literária ocorreu por meio de base de dados do google acadêmico, PubMed, Scielo e demais informações eletrônicas de respaldo no território nacional.
- Open Access
- 1 March 2025
- Published by Seven Events in ARACÊ
- Vol. 7 (3) , 12653-12672
ANÁLISE TÉCNICA DA EFICÁCIA TERAPÊUTICA DA INTRADERMOTERAPIA NO TRATAMENTO DA GORDURA LOCALIZADA
A necessidade de um padrão de beleza humano tornou-se um fenômeno comum na sociedade, fazendo com que houvesse a busca por um corpo ideal e sua reavaliação. A gordura local é definida como um distúrbio celular do metabolismo das células de gordura ou seu crescimento anormal, comum nas principais partes do corpo, como: coxas, abdômen e coxas. A Intradermoterapia é um procedimento que usa injeções intradérmicas de agentes lipolíticos altamente diluídos em uma área de gordura localizada. Ademais, este trabalho possui o objetivo de a eficácia da terapia intradérmica (Intradermoterapia) no tratamento gordura localizada. Para isso, a metodologia aplicada é qualitativa e bibliográfica, sendo que revisão literária ocorreu por meio de base de dados do google acadêmico, PubMed, Scielo e demais informações eletrônicas de respaldo no território nacional.
- 1 March 2025
- Published by Seven Events in ARACÊ
- Vol. 7 (3) , 12653-12672
Open AccessANÁLISE TÉCNICA DA EFICÁCIA TERAPÊUTICA DA INTRADERMOTERAPIA NO TRATAMENTO DA GORDURA LOCALIZADA
A necessidade de um padrão de beleza humano tornou-se um fenômeno comum na sociedade, fazendo com que houvesse a busca por um corpo ideal e sua reavaliação. A gordura local é definida como um distúrbio celular do metabolismo das células de gordura ou seu crescimento anormal, comum nas principais partes do corpo, como: coxas, abdômen e coxas. A Intradermoterapia é um procedimento que usa injeções intradérmicas de agentes lipolíticos altamente diluídos em uma área de gordura localizada. Ademais, este trabalho possui o objetivo de a eficácia da terapia intradérmica (Intradermoterapia) no tratamento gordura localizada. Para isso, a metodologia aplicada é qualitativa e bibliográfica, sendo que revisão literária ocorreu por meio de base de dados do google acadêmico, PubMed, Scielo e demais informações eletrônicas de respaldo no território nacional.
- Open Access
- 25 September 2024
- Published by Sociedade Brasileira de Nefrologia
- Vol. 46 (4 Suppl. 1) , S124
EFFECT OF FERRIC CARBOXYMALTOSE VERSUS IRON SUCROSE ON HEMATIMETRIC INDICES AND IRON PROFILE IN CHRONIC HEMODIALYSIS PATIENTS: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS
Introduction: Intravenous iron therapy plays a fundamental role in the treatment of anemia in patients with chronic kidney disease (CKD) undergoing hemodialysis, improving survival rates and quality of life. Ferric carboxymaltose (FCM) is an alternative iron compound that allows for larger single doses, resulting in less frequent administration compared to iron sucrose. Although the choice of formulation and frequency of administration vary among centers, FCM presents an effective option for patients on hemodialysis. With its stability and controlled release of iron, FCM is a valuable option for these patients. Methods: We conducted a systematic search in PubMed, Embase, and Cochrane databases for randomized controlled trials (RCTs) comparing the effect of Iron Sucrose versus Ferric Carboxymaltose in patients undergoing Chronic Hemodialysis and reporting outcomes including (1) hemoglobin (Hb), (2) ferritin, (3) adverse effects, (4) hospitalizations, and (5) mortality. Data were extracted from reports published up to May 30, 2024, and quality assessment was performed following Cochrane recommendations. We pooled mean differences (MD) for continuous outcomes, with 95% confidence intervals (CI), using a random-effects model (IV, Random, 95% CI) to accommodate variability among studies. We used R version 4.3.2 for all statistical analyses. Results: Our meta-analysis included 3 RCTs, comprising 270 patients, of whom 137 were randomized to the FCM group. Compared with the control group, FCM significantly reduced ferritin levels (MD -52.95; 95% CI: -89.43 to -16.46; p< 0.05). However, there were no significant differences in hemoglobin levels (MD -0.19; 95% CI: -0.57 to 0.18; p=0.31) between groups. This lack of significant difference suggests that treatment with FCM does not negatively affect hemoglobin levels compared to the control. Furthermore, regarding adverse effects, our meta-analysis evaluated three main categories: infection (RR 0.80; 95% CI: 0.55 to 1.14; p=0.21), local reaction (RR 0.88; 95% CI: 0.13 to 5.72; p=0.89), and drug intolerance (RR 0.98; 95% CI: 0.10 to 10.00; p=0.99). Additionally, we assessed mortality (RR 0.32; 95% CI: 0.09 to 1.15; p=0.081). Conclusion: Our meta-analysis suggests a difference in ferritin concentration between the FCM (Ferric Carboxymaltose) group and the control (Iron Sucrose) group, with the control group having higher levels than the intervention group.
- 25 September 2024
- Published by Sociedade Brasileira de Nefrologia
- Vol. 46 (4 Suppl. 1) , S124
Open AccessEFFECT OF FERRIC CARBOXYMALTOSE VERSUS IRON SUCROSE ON HEMATIMETRIC INDICES AND IRON PROFILE IN CHRONIC HEMODIALYSIS PATIENTS: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS
Introduction: Intravenous iron therapy plays a fundamental role in the treatment of anemia in patients with chronic kidney disease (CKD) undergoing hemodialysis, improving survival rates and quality of life. Ferric carboxymaltose (FCM) is an alternative iron compound that allows for larger single doses, resulting in less frequent administration compared to iron sucrose. Although the choice of formulation and frequency of administration vary among centers, FCM presents an effective option for patients on hemodialysis. With its stability and controlled release of iron, FCM is a valuable option for these patients. Methods: We conducted a systematic search in PubMed, Embase, and Cochrane databases for randomized controlled trials (RCTs) comparing the effect of Iron Sucrose versus Ferric Carboxymaltose in patients undergoing Chronic Hemodialysis and reporting outcomes including (1) hemoglobin (Hb), (2) ferritin, (3) adverse effects, (4) hospitalizations, and (5) mortality. Data were extracted from reports published up to May 30, 2024, and quality assessment was performed following Cochrane recommendations. We pooled mean differences (MD) for continuous outcomes, with 95% confidence intervals (CI), using a random-effects model (IV, Random, 95% CI) to accommodate variability among studies. We used R version 4.3.2 for all statistical analyses. Results: Our meta-analysis included 3 RCTs, comprising 270 patients, of whom 137 were randomized to the FCM group. Compared with the control group, FCM significantly reduced ferritin levels (MD -52.95; 95% CI: -89.43 to -16.46; p< 0.05). However, there were no significant differences in hemoglobin levels (MD -0.19; 95% CI: -0.57 to 0.18; p=0.31) between groups. This lack of significant difference suggests that treatment with FCM does not negatively affect hemoglobin levels compared to the control. Furthermore, regarding adverse effects, our meta-analysis evaluated three main categories: infection (RR 0.80; 95% CI: 0.55 to 1.14; p=0.21), local reaction (RR 0.88; 95% CI: 0.13 to 5.72; p=0.89), and drug intolerance (RR 0.98; 95% CI: 0.10 to 10.00; p=0.99). Additionally, we assessed mortality (RR 0.32; 95% CI: 0.09 to 1.15; p=0.081). Conclusion: Our meta-analysis suggests a difference in ferritin concentration between the FCM (Ferric Carboxymaltose) group and the control (Iron Sucrose) group, with the control group having higher levels than the intervention group.